Guggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potential

Shares of Yarrow Bioscience, Inc (NASDAQ:YARW) gained 4.3% on Friday after Guggenheim initiated coverage with a Buy rating and a $60 price target. The upbeat assessment positions the clinical-stage biotechnology firm to capture a significant share of what the brokerage frames as an underserved multibillion-dollar autoimmune market.

In a research note led by analyst Yatin Suneja, the firm characterized Graves' disease as one of the last major autoimmune conditions lacking a branded therapeutic, drawing parallels to the rheumatoid arthritis landscape two decades ago. Suneja estimates the addressable space could ultimately support a $15 billion to $20 billion commercial category.

While rival developers advance FcRn inhibitors and antibody degraders through pivotal testing, Guggenheim expressed higher conviction in anti-TSHR agents that directly disrupt the disease’s central biology. The firm highlighted that targeted TSHR blockers offer a viable clinical path in thyroid eye disease (TED), an adjunctive condition where competing FcRn candidates have faced developmental setbacks.

Yarrow’s lead asset, YB-101, stands as one of the most clinically advanced candidates within the TSHR blocker class. Early clinical and preclinical evaluations suggest the mechanism effectively addresses the underlying root cause of the disorder, reinforcing the brokerage’s constructive stance ahead of anticipated Phase IIa readouts in the second half of 2027.

If approved, Guggenheim models global peak sales of roughly $2.5 billion for YB-101, translating to an estimated $1.5 billion on a risk-adjusted basis. That commercial trajectory underpins the firm’s $60 target, leaving investors focused on upcoming mid-stage clinical milestones as the primary catalyst for valuation re-rating.